Pharmacyclics, an AbbVie Company
Pharmacyclics is an AbbVie company focused on developing and commercializing innovative small-molecule therapies for the treatment of certain cancers and immune-mediated diseases. Our hope is that we can change or improve the standard of care for the disease areas we treat or study to continually advance cancer care. Pharmacyclics and its partner Janssen Biotech, developed and commercialize IMBRUVICA® (ibrutinib), a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). Pharmacyclics is located in Sunnyvale, California, in Silicon Valley.